Structural and functional characterization of MAVS DDX3 vRNA complex
The mitochondrial antiviral signalling (MAVS) adaptor protein is a central signalling hub for host cells to mount an antiviral response following RNA virus infections, which is initiated by the cytosolic receptors that trigger the...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
UncoveRNAi
Deciphering the mechanisms of antiviral RNA interference in...
213K€
Cerrado
ENVISION
Novel mechanisms of early defense against virus infections
2M€
Cerrado
ANTIViR
Molecular mechanisms of interferon induced antiviral restric...
1M€
Cerrado
AntiViralEvo
Unravelling the evolution of antiviral sensors and response...
2M€
Cerrado
V-RNA
Two facets of viral RNA mechanistic studies of transcriptio...
2M€
Cerrado
RYC-2017-21986
Mechanisms of RNA viruses to counteract the host immune resp...
309K€
Cerrado
Información proyecto MDR
Duración del proyecto: 40 meses
Fecha Inicio: 2019-04-10
Fecha Fin: 2022-08-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The mitochondrial antiviral signalling (MAVS) adaptor protein is a central signalling hub for host cells to mount an antiviral response following RNA virus infections, which is initiated by the cytosolic receptors that trigger the type-I interferon (INFs) path through the MAVS. Recently, it has been shown that the RNA helicase DDX3 is a novel atypical member of the viral cytosolic receptor pool and it is required to activate the MAVS during the antiviral response. In fact, DDX3 is crucial in the translation initiation of the HIV-1 RNA and it is identified as viral RNA sensor able to induce the antiviral immunity in dendritic cells (DCs). DDX3 binds to viral RNAs lacking the poly(A) tails, also known as abortive transcripts, and then associates with the MAVS to trigger the production of type I IFN.
Currently, it is unknown how the complex partners MAVS-DDX3-vRNA (MDR) interact for assembly and what is the MDR mechanism of action at molecular level.
The proposed research will be focused on the structural and functional characterization of the MDR complex by biophysical and cellular biology techniques. Notably, silencing DDX3 or MAVS expression suppress DC activation in response to HIV-1 infection, an event that in physiological condition is at the front line of host defence against the HIV-1. Therefore, the central role in triggering antiviral immune response makes MDR a strategic pharmacological target. However, addressing this task requires the MDR structure elucidation in order to exploit its molecular features to create a new generation of adjuvants in anti-retroviral therapy.
This research provides an understanding of how cellular protein sensors interact with retroviral RNA to trigger the native immune response and induce expression of antiviral proteins.